Unknown

Dataset Information

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.


ABSTRACT:

Background and objectives

It was postulated that in patients with membranous nephropathy (MN), four weekly doses of Rituximab (RTX) would result in more effective B cell depletion, a higher remission rate, and maintaining the same safety profile compared with patients treated with RTX dosed at 1 g every 2 weeks. This hypothesis was supported by previous pharmacokinetic (PK) analysis showing that RTX levels in the two-dose regimen were 50% lower compared with nonproteinuric patients, which could potentially result in undertreatment.

Design, setting, participants, & measurements

Twenty patients with MN and proteinuria >5 g/24 h received RTX (375 mg/m(2) × 4), with re-treatment at 6 months regardless of proteinuria response. PK analysis was conducted simultaneously with immunol

SUBMITTER: Fervenza FC 

PROVIDER: S-EPMC2994079 | biostudies-literature | 2010 Dec

REPOSITORIES: biostudies-literature